Angiotensin receptor-neprilysin inhibitor therapy and cardiac remodeling in heart failure: consensus statement from India

H. K. Chopra, G. S. Wander, Tiny Nair, C. K. Ponde, Navin C. Nanda, Jagat Narula, Saumitra Ray, K. Venugopal, S. S. Iyengar, R. R. Kasliwal, Praveen Chandra, Sunil Prakash, Sandeep Bansal, D. S. Rana, Prafulla Kerkar, Arup Dasbiswas, J. P.S. Sawhney, S. Shanmungasundram, Viveka Kumar, I. B. VijayalakshmiA. K. Pancholia, Vinod Sharma, Aditya Kapoor, Onkar C. Swami, H. S. Isser, Vishal Rastogi, Y. K. Arora, Ashok K. Omar, Sunil Sathe, Rajeeve Rajput, D. Prabhakar, G. Justin Paul, Priya Jagia, Poonam Malhotra, G. Suryaprakash, Vinod Mittal, Manish Jagia, A. Jabir, S. S. Mishra, S. N. Routray, Ajay Kumar Sinha, Mohan Bhargava, Kiran Mahmood, Shreya Lal, Dhammdeep Dabhade, Mona Bhatia, Pramila Kalra, V. K. Katyal, Rohit Tandon, Rahul Grover, Abhinav Chhabra, N. R. Shastry

Research output: Contribution to journalReview articlepeer-review


Adverse cardiac remodeling refers to progressive structural and functional modifications in the heart because of increased wall stress in the myocardium, loss of viable myocardium, and neurohormonal stimulation. The guideline-directed medical therapy for Heart failure (HF) includes Angiotensin receptor-neprilysin inhibitor (ARNI) (sacubitril/valsartan), β-blockers, sodium-glucose co-Transporter 2 (SGLT2) inhibitors, and mineralocorticoid receptor antagonists (MRA). ARNI is under-prescribed in India despite its attractive safety and efficacy profile. Therefore, the consensus discusses objectives and topics related to ARNI in the management of cardiac remodeling, and experts shared their views on the early timely intervention of effective dosage of ARNI to improve the diagnosis and enhance mortality and morbidity benefits in cardiac reverse remodeling (CRR).

Original languageEnglish
Pages (from-to)73-82
Number of pages10
JournalThe Journal of the Association of Physicians of India
Issue number4
StatePublished - Apr 2023


Dive into the research topics of 'Angiotensin receptor-neprilysin inhibitor therapy and cardiac remodeling in heart failure: consensus statement from India'. Together they form a unique fingerprint.

Cite this